ReShape Lifesciences Inc. Quarterly Operating Income (Loss) in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
ReShape Lifesciences Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2024.
  • ReShape Lifesciences Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$2.05M, a 48.3% increase year-over-year.
  • ReShape Lifesciences Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$10M, a 74% increase year-over-year.
  • ReShape Lifesciences Inc. annual Operating Income (Loss) for 2023 was -$15.4M, a 66.8% increase from 2022.
  • ReShape Lifesciences Inc. annual Operating Income (Loss) for 2022 was -$46.4M, a 19.9% increase from 2021.
  • ReShape Lifesciences Inc. annual Operating Income (Loss) for 2021 was -$57.9M, a 365% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$10M -$2.05M +$1.92M +48.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$12M -$2.21M +$3.42M +60.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$15.4M -$1.9M +$14.8M +88.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$30.2M -$3.88M +$8.42M +68.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$38.6M -$3.98M +$5.27M +57% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$43.9M -$5.63M +$2.48M +30.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$46.4M -$16.7M +$20.8M +55.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$67.2M -$12.3M +$2.12M +14.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$69.3M -$9.24M -$5.56M -151% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$63.7M -$8.11M -$5.86M -259% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$57.9M -$37.5M -$35.1M -1479% Oct 1, 2021 Dec 31, 2021 10-K 2023-04-17
Q3 2021 -$22.7M -$14.4M -$12.2M -564% Jul 1, 2021 Sep 30, 2021 10-K 2023-04-17
Q2 2021 -$10.5M -$3.69M -$691K -23% Apr 1, 2021 Jun 30, 2021 10-K 2023-04-17
Q1 2021 -$9.8M -$2.26M +$2.65M +54% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-23
Q4 2020 -$12.5M -$2.38M +$2.6M +52.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-04-08
Q3 2020 -$15.1M -$2.17M +$1.57M +42% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$16.6M -$3M +$3.42M +53.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$20M -$4.91M +$3.19M +39.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 -$23.2M -$4.98M +$3.69M +42.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$26.9M -$3.74M +$2.89M +43.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$29.8M -$6.41M +$3.19M +33.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-30
Q1 2019 -$33M -$8.1M +$3.97M +32.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-06-19
Q4 2018 -$37M -$8.66M +$1.26M +12.7% Oct 1, 2018 Dec 31, 2018 10-K 2019-02-22
Q3 2018 -$38.2M -$6.64M +$2.5M +27.4% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$40.7M -$9.6M -$1.96M -25.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-24
Q1 2018 -$38.8M -$12.1M -$4.38M -56.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 -$34.4M -$9.92M -$2.39M -31.7% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-22
Q3 2017 -$32M -$9.14M -$4.69M -105% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-22
Q2 2017 -$27.3M -$7.64M -$3.57M -87.5% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-22
Q1 2017 -$23.8M -$7.69M -$4.25M -123% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-22
Q4 2016 -$19.5M -$7.53M -$2.86M -61.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-05
Q3 2016 -$16.6M -$4.45M -$1.08M -32.1% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-05
Q2 2016 -$15.6M -$4.08M +$794K +16.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-05
Q1 2016 -$16.4M -$3.44M -$1.42M -70.5% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-05
Q4 2015 -$14.9M -$4.67M Oct 1, 2015 Dec 31, 2015 10-K 2017-02-23
Q3 2015 -$3.37M Jul 1, 2015 Sep 30, 2015 10-K 2017-02-23
Q2 2015 -$4.87M Apr 1, 2015 Jun 30, 2015 10-K 2017-02-23
Q1 2015 -$2.02M Jan 1, 2015 Mar 31, 2015 10-K 2017-02-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.